<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653377</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0144</org_study_id>
    <secondary_id>2018-A01314-51</secondary_id>
    <nct_id>NCT03653377</nct_id>
  </id_info>
  <brief_title>Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)</brief_title>
  <official_title>Survey on the Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis Followed in Cystic Fibrosis (CF) Center in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background The main risk factor for cervical cancer is the infection by human papillomavirus
      (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of
      prevention against cervical pathology. Despite this, vaccination coverage against HPV remains
      low in France. A proportion of women with cystic fibrosis may be involved in transplantation,
      a factor associated with a higher risk of HPV carriage and cervical pathology. An over-risk
      of cervical pathology would also be present in women with non-transplanted cystic fibrosis.
      Particular attention to vaccination should therefore be included in this population.

      Objectives of the study The main objective of the study is to estimate the frequency of HPV
      vaccination in young girls with CF over 9 years and followed in a pediatric CF center.

      The secondary objectives are to know:

        -  The type of vaccine used (bivalent / quadrivalent / nonavalent)

        -  The proportion of vaccinated girls with respect of the vaccination schedule (number of
           injections / spacing between doses)

        -  Reasons for non-use of vaccination

      Study design The study will last 12 months. It is a cross-sectional, non-interventional,
      multicenter conducted by self-administered questionnaire.

      Population

        -  young girls aged 9 years or older with Cystic fibrosis

        -  Followed in a pediatric or mixed CF center in the France (Rhone-Alpes Auvergne Region
           and Ile de France Region)

        -  With parents who did not object to participation in the study

      Number of subject: 62 patients

      Expected results

        -  Knowledge of HPV vaccination coverage in young girls with CF.

        -  Sensitization of patients, their parents and health professionals to HPV vaccination.
           Understand the barriers and reasons for refusing vaccination to promote actions to
           improve immunization coverage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HPV vaccination</measure>
    <time_frame>Baseline</time_frame>
    <description>The outcome measure is having HPV vaccination. This information is collected through a self-questionnaire, completed by the patients or their parents, during a visit to the CF center</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Mucoviscidosis</condition>
  <arm_group>
    <arm_group_label>Patients with self-administered questionnaire</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self administrated questionnaire</intervention_name>
    <description>Questionnaires are distributed to patients with their parents during their visit to the CF center.</description>
    <arm_group_label>Patients with self-administered questionnaire</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of minor girls with cystic fibrosis older than 9 years, followed in a pediatric
        Mucoviscidosis Resource and Competence Center (MRCC).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  young girls aged 9 years or older

          -  patients with Cystic Fibrosis

          -  patients followed in a pediatric or mixed CF center in the France (Rhone-Alpes
             Auvergne Region and Ile de France Region)

          -  patients with parents who did not object to participation in the study

        Exclusion Criteria:

        -patients who refuse to answer to the self-administrated questionnaire
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
    <phone>04.78.56.90.49</phone>
    <phone_ext>+33</phone_ext>
    <email>christine.rousset-jablonski@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine TOUZET, MD</last_name>
    <phone>04 72 11 57 61</phone>
    <phone_ext>+33</phone_ext>
    <email>sandrine.touzet@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Mucoviscidose, Pneumologie</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe REIX, MP</last_name>
      <phone>04.27.85.54.70</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.reix@chu.lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe REIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>André LABBE, MP</last_name>
      <phone>04 73 75 06 11</phone>
      <phone_ext>+33</phone_ext>
      <email>alabbe@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>André LABBE, MP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Couple / Enfant</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle PIN, MD</last_name>
      <phone>04 76 76 51 89</phone>
      <phone_ext>+33</phone_ext>
      <email>ipin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle PIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM, Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Michèle Gerardin, MD</last_name>
      <phone>01 40 03 47 54</phone>
      <phone_ext>+33</phone_ext>
      <email>michele.gerardin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Michèle Gerardin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM, Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Corvol, MP</last_name>
      <phone>01 44 73 68 77</phone>
      <phone_ext>+33</phone_ext>
      <email>harriet.corvol@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Harriet Corvol, MP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM, Institut Necker Enfants Malade</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Sermet-Gaudelus, MP</last_name>
      <phone>01 44 49 48 87</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.sermet@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Sermet-Gaudelus, MP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Ressources et de Compétences de la Mucoviscidose Adultes</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
      <phone>04.78.56.90.49</phone>
      <phone_ext>+33</phone_ext>
      <email>christine.rousset-jablonski@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sandrine TOUZET, MD</last_name>
      <phone>04 72 11 57 61</phone>
      <phone_ext>+33</phone_ext>
      <email>sandrine.touzet@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mucoviscidosis</keyword>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Young girl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

